Head And Shoulders 2in1 Men Advanced Series Charcoal

Pyrithione Zinc


The Procter & Gamble Manufacturing Company
Human Otc Drug
NDC 69423-267
Head And Shoulders 2in1 Men Advanced Series Charcoal also known as Pyrithione Zinc is a human otc drug labeled by 'The Procter & Gamble Manufacturing Company'. National Drug Code (NDC) number for Head And Shoulders 2in1 Men Advanced Series Charcoal is 69423-267. This drug is available in dosage form of Lotion/shampoo. The names of the active, medicinal ingredients in Head And Shoulders 2in1 Men Advanced Series Charcoal drug includes Pyrithione Zinc - 1 g/100mL . The currest status of Head And Shoulders 2in1 Men Advanced Series Charcoal drug is Active.

Drug Information:

Drug NDC: 69423-267
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Head And Shoulders 2in1 Men Advanced Series Charcoal
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Pyrithione Zinc
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: The Procter & Gamble Manufacturing Company
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Lotion/shampoo
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:PYRITHIONE ZINC - 1 g/100mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 05 Jun, 2018
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 01 Aug, 2023
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: M032
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 10 May, 2026
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:The Procter & Gamble Manufacturing Company
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:209884
1043244
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:R953O2RHZ5
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
69423-267-38380 mL in 1 BOTTLE, PLASTIC (69423-267-38)05 Jun, 201801 Aug, 2023No
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose anti-dandruff

Product Elements:

Head and shoulders 2in1 men advanced series charcoal pyrithione zinc water sodium lauryl sulfate sodium laureth-3 sulfate glycol distearate zinc carbonate sodium chloride sodium xylenesulfonate dimethicone cocamidopropyl betaine cetyl alcohol sodium benzoate guar hydroxypropyltrimonium chloride (1.7 substituents per saccharide) magnesium carbonate hydroxide methylchloroisothiazolinone methylisothiazolinone coco monoethanolamide activated charcoal pyrithione zinc pyrithione zinc menthol, unspecified form stearyl alcohol fd&c yellow no. 5 d&c red no. 33 fd&c blue no. 1

Indications and Usage:

Uses helps prevent recurrence of flaking and itching associated with dandruff.

Warnings:

Warnings for external use only. when using this product avoid contact with eyes. if contact occurs, rinse eyes thoroughly with water. stop use and ask a doctor if condition worsens or does not improve after regular use of this product as directed. keep this and all drugs out of reach of children. if swallowed, get medical help or contact a poison control center right away.

Do Not Use:

Warnings for external use only. when using this product avoid contact with eyes. if contact occurs, rinse eyes thoroughly with water. stop use and ask a doctor if condition worsens or does not improve after regular use of this product as directed. keep this and all drugs out of reach of children. if swallowed, get medical help or contact a poison control center right away.

When Using:

When using this product avoid contact with eyes. if contact occurs, rinse eyes thoroughly with water.

Dosage and Administration:

Directions for best results use at least twice a week or as directed by a doctor. for maximum dandruff control, use every time you shampoo. shake before use. wet hair, massage onto scalp, rinse, repeat if desired.

Stop Use:

Stop use and ask a doctor if condition worsens or does not improve after regular use of this product as directed.

Package Label Principal Display Panel:

Principal display panel - 380 ml bottle label head & shoulders ® pyrithione zinc dandruff shampoo 2in1 men advanced series tm charcoal purify scalp with a powerful clean infused with charcoal flake free * up to 100% guaranteed 12.8 fl oz (380 ml) hs

Further Questions:

Questions (or comments)? 1-800-723-9569


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.